Evaluation of a New Strategy for the Diagnosis of Peroxisomal Diseases

Diagnoses Disease Clinical Trial

— PEROXY4G  

Official title:

Evaluation of a New Strategy for the Diagnosis of Peroxisomal Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03163771
• Other study ID #: 2015_12
• Secondary ID: 2016-A01147-44PH
• Status: Recruiting
• Start date: December 17, 2018
• Est. completion date: December 2023

Study information

• Verified date: February 2023
• Source: University Hospital, Lille
• Contact: Joseph VAMECQ, MD
• Phone: +33 320 44 56 94
• Email: joseph.vamecq[@]chru-lille.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The principal aim of the study is to avoid the diagnostic wanderings of patients suffering from a peroxisomal disorder. For this purpose, a new diagnostic strategy is proposed. It rests on functional metabolic explorations and gene studies directly connected to a first-line enlarged physico-chemical detection of metabolites from peroxisomal origin in clinically suspect patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

I - CLINICAL/BIOLOGICAL CRITERIA For an efficient screening of the patients of the 4 contributing University Hospitals (Amiens, Caen, Lille and Rouen), various inclusion criteria were selected: In general, the inclusion criterion is the existence of a positive biology or in turn the persistence of a clinical suspicion in spite of a negative biology. I A - Children from 0 to 17 years: The clinical inclusion criterion is a positive biology or the persistence of a clinical suspicion in spite of a negative biology. This persistent clinical suspicion is left to the discretion of the clinician. It is essentially based on the existence of a family history of peroxisomal (or suspected) pathology and / or the combination of several clinical signs of craniofacial dysmorphism, skeletal abnormalities, encephalopathy (seizures, ataxia, Hypotonia), demyelinating peripheral neuropathy, ophthalmopathy (retinopathy, cataract), hepatic impairment (hyperbilirubinemia, hepatomegaly, cholestasis) and growth retardation OR I B - Adults from 18 years The neurological symptoms of peroxisomal diseases in adulthood are numerous and

non-specific. The three inclusion criteria selected for patient selection are as follows:

• Cognitive impairment (delayed acquisition or regression) and / or leukodystrophy AND At least one of the following signs: Cerebellar ataxia, Spastic paraparesis, Peripheral neuropathy, Neurosensory deafness, Retinitis pigmentosa, Epilepsy, Unexplained unexplained vigilance, Peripheral corticotropic insufficiency +/- gonadotropic AND
• no evidence for an extraperoxisomal origin of the patient disease stated after the usual paraclinic explorations II - NON CLINICAL CRITERIA
• Social insurances
• Having understood the information note and having signed the informed consent form.
• Patients under guardianship or curatorship may be included, since peroxisomal diseases as a cause of neurological impairment may potentially lead to guardianship.

Exclusion Criteria:

• Pregnant or nursing women
• Person deprived of liberty or in emergency situations

Related Conditions & MeSH terms

• Diagnoses Disease
• Disease
• Peroxisomal Disorders

Locations

Country	Name	City	State
France	Département de Pédiatrie, Unité de Génétique Clinique, CHU d'Amiens	Amiens
France	Pédiatrie, CHU Clémenceau de Caen	Caen
France	Hôpital Jeanne de Flandres, CHRU	Lille
France	Pédiatrie, Pavillon Mère et Enfant, CHU Ch. Nicolle de Rouen	Rouen

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Lille	Ministry of Health, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of cases diagnosed by the new procedure versus the number of patients included.	Evaluation of a diagnostic strategy based on functional metabolic explorations and gene studies directly connected to a first-line enlarged physico-chemical detection of metabolites from peroxisomal origin in clinically or biologically suspect patients; The study is concomitant with an implementation in the routine Hospitals of the inter-region (West and North of France) of an immediate wide exploration (and not sequential and optional) of diagnostic markers of a pathology peroxisomal. This wide exploration should by itself lead to a diagnosis enrichment and should increase the number of inclusions. But the study, for patients thus included, is also considering an enlarged scanning of functional and genetic explorations that follow inclusion (instead of targeted screening guided primarily by the biological anomaly in the usual practice).	14 months
Secondary	Number of new cases diagnosed by the new procedure in relation to the number of habitants per year.	Evaluation of a diagnostic strategy based on functional metabolic explorations	14 months